Proteins From Mammals Or Birds Patents (Class 530/827)
  • Patent number: 8912147
    Abstract: The invention provides fusion protein constructs comprising a functional mitochondrial protein and methods of treating mitochondrial disorders by the fusion proteins and compositions thereof.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: December 16, 2014
    Assignee: BioBlast Pharma Ltd.
    Inventor: Haya Lorberboum-Galski
  • Patent number: 8846603
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: September 30, 2014
    Assignee: Synageva Biopharma Corp.
    Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
  • Patent number: 8258271
    Abstract: The invention describes isolated mTOR-associated proteins (“mTOR-APs”) as well as isolated variants and fragments thereof and the isolated nucleic acids encoding them. The invention also describes vectors and host cells containing nucleic acid encoding an mTOR-AP polypeptide and methods for producing an mTOR-AP polypeptide. Also described are methods for screening for compounds which modulate mTOR-AP activity and methods for treating or preventing a disorder that is responsive to mTOR-AP modulation.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: September 4, 2012
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David M. Sabatini, Do-Hyung Kim, Dos D. Sarbassov
  • Patent number: 7670763
    Abstract: This invention describes unique patterns of distribution of ganglioside GM1 in non-capacitated sperm and demonstrates that the pattern of distribution of GM1 undergoes changes that can be correlated with the process of capacitation and/or with acrosomal exocytosis. Accordingly, the present invention discloses a method for determining the ability of sperm to respond to capacitation and/or acrosomal exocytosis stimuli. The method comprises determination of distribution pattern for GM1. The method can be used for both diagnostic and predictive purposes when assessing male reproductive fitness, and can also be used to assess the effects on sperm of cryoprotective agents and protocols, and contraceptive agents.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: March 2, 2010
    Assignees: Cornell Research Foundation, Inc., Trustees of the University of Pennsylvania
    Inventors: Alexander J. Travis, Gregory S. Kopf
  • Patent number: 7572890
    Abstract: Recombinant Human Mannan-Binding Proteins (rhMBP) having physiological activities which are substantially identical to those offered by Human Mannan-Binding Proteins (hMBP), as well as, in particular, a production system for homogenously producing rhMBP having the specific peaks at the molecular weight of 1,000˜1,300 kDa determined by absorbance (280 nm) in Gel-Filtration Chromatography are provided.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: August 11, 2009
    Assignee: Fuso Pharmaceutical Industries, Ltd.
    Inventor: Nobutaka Wakamiya
  • Patent number: 7425616
    Abstract: The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: September 16, 2008
    Assignee: STC.UNM
    Inventors: Terry W. Du Clos, Carolyn Mold
  • Patent number: 7226994
    Abstract: We describe two primordial germ cell-specifically expressed genes, GCR1 (Fragilis) and GCR2 (Stella), as well as their fragments, homologues, variants or derivatives thereof which are markers for primordial germ cells and may be used to identify such cells in cell populations.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: June 5, 2007
    Assignee: Cambridge University Technical Services Limited
    Inventors: Mitinori Saitou, Azim Surani
  • Patent number: 7226995
    Abstract: The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: June 5, 2007
    Assignee: STC.UNM
    Inventors: Terry Du Clos, Carolyn Mold
  • Patent number: 7199218
    Abstract: The invention concerns a novel ICBP90 (Inverted CCAAT box binding protein 90) and its fragments, polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides. The invention also concerns methods and kits for diagnosing cell proliferation and compounds useful as medicine for preventing and/or treating pathology involving cell proliferation and in particular cancer.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: April 3, 2007
    Assignee: Institut National de la Sante et de la Recherche Medicale :(INSERM)
    Inventors: Christian Bronner, Raphaël Hopfner, Marc Mousli, Jean-Marc Jeltsch, Yves Lutz, Pierre Oudet
  • Patent number: 7183382
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: February 27, 2007
    Assignee: Schering Corporation
    Inventors: Birgit Oppmann, Rene De Waal Malefyt, Donna M. Rennick, Robert A. Kastelein, Maria T. Wiekowski, Sergio A. Lira, Satwant K. Narula
  • Patent number: 7160676
    Abstract: This invention describes unique patterns of distribution of ganglioside GM1 in non-capacitated sperm and demonstrates that the pattern of distribution of GM1 undergoes changes that can be correlated with the process of capacitation and/or with acrosomal exocytosis. Accordingly, the present invention discloses a method for determining the ability of sperm to respond to capacitation and/or acrosomal exocytosis stimuli. The method comprises determination of distribution pattern for GM1. The method can be used for both diagnostic and predictive purposes when assessing male reproductive fitness, and can also be used to assess the effects on sperm of cryoprotective agents and protocols, and contraceptive agents.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: January 9, 2007
    Assignees: Cornell Research Foundation, Inc., Trustees of the University of Pennsylvania
    Inventors: Alexander J. Travis, Gregory S. Kopf
  • Patent number: 7019114
    Abstract: The invention relates to methods for producing recombinant human zona pellucida protein (“rhZP3”) and glycosylated peptide having biological activity of binding to human spermatozoa. A human ovarian cell line is used to produce rhZP3 having a glycosylation pattern required for full biological activity. Methods of determining useful peptides with binding activity for human sperm and their syntheses, as well as using such peptides and proteins in therapeutics and diagnostics are discussed.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: March 28, 2006
    Assignee: Eastern Virginia Medical School
    Inventors: Ke-Wen Dong, Sergio Oehninger, William E. Gibbons
  • Patent number: 7001985
    Abstract: This invention relates to a novel protein having a high degree of homology to the amino acid sequence of the so-called cyclin box which is characteristic of cyclins: they are herein referred to as “human cyclin I” or “human cyclin I protein.” Further, the invention relates to a gene encoding their amino acid sequences and the protein: the gene is referred to as “gene encoding human cyclin I” or “human cyclin I gene.” Also, the invention relates to expression vector into which the human cyclin I gene is incorporated as well as to a transformant into which the vector is introduced. Still further, the invention relates to a recombinant protein obtained by growing the transformant. In addition, the invention relates to a novel neuron-marking method using an anitisense nucleotide of the gene as probe. Furthermore, the invention relates to method for screening cancer cell using the human cyclin I gene.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: February 21, 2006
    Assignee: Sumitomo Electric Industries, Ltd.
    Inventor: Takeshi Nakamura
  • Patent number: 6930169
    Abstract: The present invention describes a calcium-binding myristoylated protein with homology to calcineurin B which interacts preferentially with presenilin 2 protein. Also, the present invention relates to methods that alter protein-protein interaction of the calcium-binding myristoylated protein with presenilin 2 thereby reducing deleterious effects of the protein-protein interaction, such as apoptosis. The present invention further relates to introducing and expressing a mutant presenilin 2 protein or mutant calcium-binding myristoylated protein to modulate cell functions relating to calcium signaling and apoptosis.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: August 16, 2005
    Assignee: University of Baltimore Biotechnology Institute
    Inventors: Mervyn J. Monteiro, Stacy Stabler
  • Patent number: 6841644
    Abstract: Disclosed are modified naturally occurring biocompatible biopolymers of plant and animal origin made by subjecting same to ionizing radiation in the presence of a mediating gas, typically acetylene to enable one to selectively enhance and modify one or more of the physiochemical properties of the starting materials which have a wide range of uses in medicine, food technology and other industrial applications. Notwithstanding the modifications, the biocompatibility of the biopolymer remains unchanged and no new or additional functional groups are introduced into the starting biopolymer.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: January 11, 2005
    Assignee: Phillips Hydrocolloids Research Limited
    Inventors: Glyn Owen Phillips, Tjaart Andries Du Plessis, Saphwan Al-Assaf, Peter Anthony Williams
  • Patent number: 6767711
    Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: July 27, 2004
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Neil H. Bander
  • Patent number: 6680370
    Abstract: The present invention provides a DNA expressed at high frequency in mesangial cells and a protein (Meg-4) encoded by this DNA. These substances are useful in, for example, identifying mesangial cells and detecting abnormalities in mesangial cells. Moreover, the above protein would be helpful for clarification of the functions of mesangial cells and, in its turn, for clarification of the causes of diseases relating to mesangial cells. This protein is expectedly applicable to the treatment, diagnosis, and such of diseases relating to mesangial cells.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: January 20, 2004
    Assignees: Tokai University Educational System
    Inventor: Toshio Miyata
  • Patent number: 6670123
    Abstract: The present invention provides an isolated nucleic acid encoding KIAA0918, an isolated nucleic acid that hybridizes under high stringency conditions to a nucleic acid that is complementary to a nucleic acid encoding KIAA0918, a purified KIAA0918 protein, a purified protein encoded by a nucleic acid that hybridizes under high stringency conditions to a nucleic acid that is complementary to a nucleic acid encoding KIAA0918, a method of making KIAA0918 protein, an antibody specific for KIAA0918, a method for producing an antibody specific for KIAA0918 protein, a vector comprising a nucleic acid encoding KIAA0918, and a host cell transformed with a vector comprising a nucleic acid encoding KIAA0918. Also provided are methods for detecting the presence of and isolating hematopoietic stem cells in a heterogeneous cell suspension and for assessing gene expression in a tissue sample.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: December 30, 2003
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander Belyavsky, Sergey Shmelkov, Jan Visser
  • Patent number: 6638725
    Abstract: The present invention provides a method capable of simultaneous processing of plural test samples for the receptor binding property of a chemical substance, which does not require immobilization of the receptor or a special device, and a reagent to be used for this method. That is a method for assaying the receptor binding property of an assay target substance is provided, the method comprising the steps of (a) competitively reacting a known concentration of a ligand and the assay target substance with a known concentration of the receptor in a solution, (b) measuring, without physically removing the ligand bound with the receptor prior to the assay, the amount of a free ligand in the solution using one or more antibodies against the ligand, and (c) determining the receptor binding property of the assay target substance using the amount of the free ligand as an index.
    Type: Grant
    Filed: January 24, 2000
    Date of Patent: October 28, 2003
    Assignee: Toyo Boseki Kabushiki Kaisha
    Inventors: Yoshihiro Soya, Shigeaki Nishii, Kazuhiro Matsui, Takuya Ishibashi, Yoshihisa Kawamura
  • Patent number: 6635744
    Abstract: The invention provides fibroblast growth factor homologous factor (FHF) polypeptides and nucleic acid molecules that encode them. Also included in the invention are diagnostic and therapeutic methods using FHF polypeptides and nucleic acids.
    Type: Grant
    Filed: January 25, 2000
    Date of Patent: October 21, 2003
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Jeremy Nathans, Philip M. Smallwood
  • Patent number: 6605280
    Abstract: Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: August 12, 2003
    Assignee: Yeda Research and Development Company Limited
    Inventors: Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Hyun Kim
  • Patent number: 6576417
    Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: June 10, 2003
    Assignee: Innogenetics, N.V.
    Inventors: Robert J. Deleys, Dirk Pollet, Geert Maertens, Hugo Van Heuverswijn
  • Patent number: 6514701
    Abstract: Novel peptide analogs derived from the native sequences of CAP37 peptides 20-44 and 23-42, and their use as therapeutics against bacterial infections and diseases caused by bacterial infection. The peptide analog includes a serine or threonine substitution at one of the two cysteine residues at positions 26 and 42. Substitutions of the native peptide are also contemplated.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: February 4, 2003
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: H. Anne Pereira
  • Patent number: 6506570
    Abstract: A method of determining the gender of a bird in ovo comprises detecting the presence or absence of an elevated level of a sex-related hormone in the extra-embryonic fluid of the bird egg, and then determining the gender of the bird within the egg from the presence of an elevated level of a sex-related hormone therein. Preferably, the sex-related hormone is an estrogen. Further preferred are methods in which the extra-embryonic fluid is allantoic fluid. The method is preferably carried out on chicken eggs prior to or during transfer of the eggs from incubator to hatcher.
    Type: Grant
    Filed: March 23, 1999
    Date of Patent: January 14, 2003
    Assignee: Embrex, Inc.
    Inventor: Patricia V. Phelps
  • Patent number: 6469139
    Abstract: The present invention relates to modified human chorionic gonadotropin (&bgr;-hCG) proteins and their medical use as immunological contragestatives. The modification causes a reduction in the cross-reactivity of the modified &bgr;-hCG protein with luteinizing hormone (LH) as defined by the ability of both proteins to react with the same antibody.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: October 22, 2002
    Assignee: University College London
    Inventors: Ivan Maurice Roitt, Peter John Delves, Torben Lund
  • Patent number: 6455493
    Abstract: The present invention provides a heat shock protein immunotoxin comprising: at least a fragment of a heat shock protein, the fragment being capable of being bound by an immune cell; and a toxin bound to the fragment. The present invention also provides a method for decreasing the number of immune cells in an individual using the heat shock protein immunotoxins of the present invention. In addition, the present invention provides a method for decreasing the number of immune cells in an organ using the heat shock protein immunotoxins of the present invention.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: September 24, 2002
    Assignee: University of New Mexico
    Inventors: Erik Wallen, Pope L. Moseley
  • Patent number: 6420534
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: July 16, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • Patent number: 6403093
    Abstract: An isolated nucleic acid molecule associated with human granulocytic ehrlichiosis is provided. Also provided are methods to detect the presence of the nucleic acid molecule, and antibodies specific for the polypeptide encoded by the nucleic acid molecule, in a sample derived from a mammal.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: June 11, 2002
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: David H. Persing, Elizabeth S. Bruinsma
  • Patent number: 6388062
    Abstract: Modified p53 tetramerization domains which do not hetero-oligomerize with native p53 tetramerization domains are described. These modified p53 tetramerization domains have one or more of the following substitutions in the region of residues 325 to 355 of human p53: Leu330 substituted with Phe; Met340 substituted with Phe; Ala347 substituted with Ile; Leu348 substituted with Met; Ala353 substituted with Leu; Gln354 substituted with Leu; Ala355 substituted with Asp. Also described are p53 proteins containing these modified p53 tetramerization domains linked to a p53 DNA binding domain. These proteins and the nucleic acid sequences encoding them, are useful in ameliorating conditions associated with inappropriate p53 function.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: May 14, 2002
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Thanos D. Halazonetis, Elena S. Stavridi
  • Patent number: 6372453
    Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN. by providing NTNR&agr; to the cell.
    Type: Grant
    Filed: February 18, 1997
    Date of Patent: April 16, 2002
    Assignee: Genetech, Inc.
    Inventors: Robert D. Klein, Arnon Rosenthal
  • Patent number: 6372473
    Abstract: The present invention relates to a novel t-PALP protein which is a member of the serine protease family. In particular, isolated nucleic acid molecules are provided encoding the human t-PALP protein. t-PALP polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of t-PALP activity. Also provided are diagnostic methods for detecting circulatory system-related disorders and therapeutic methods for treating circulatory system-related disorders.
    Type: Grant
    Filed: October 4, 1999
    Date of Patent: April 16, 2002
    Assignee: Human Genome Sciences, Inc.
    Inventors: Paul A. Moore, Steven M. Ruben, Reinhard Ebner
  • Patent number: 6365339
    Abstract: Disclosed is a method for gender determination of avian embryos. During the embryo incubation process, the outer hard shells of eggs are drilled and samples of allantoic fluid are removed. The allantoic fluids are directly introduced into an ion mobility spectrometer (IMS) for analysis. The resulting spectra contain the relevant marker peaks in the positive or negative mode which correlate with unique mobilities which are sex-specific. This way, the gender of the embryo can be determined.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: April 2, 2002
    Assignee: Bechtel BWXT Idaho, LLC
    Inventors: Keith A. Daum, David A. Atkinson
  • Publication number: 20020038003
    Abstract: The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.
    Type: Application
    Filed: June 4, 2001
    Publication date: March 28, 2002
    Inventors: Michael J.P. Lawman, Patricia Lawman
  • Patent number: 6340667
    Abstract: The present invention provides compositions useful as antimicrobial agents which include reptilian hemoglobin, the &agr; and &bgr; chains of hemoglobin free of heme, fragments of said proteins or polypeptide fragments thereof and combinations thereof. The compositions exert antimicrobial activity against both bacteria and fungi that is comparable to known antimicrobial peptides from human neutrophils, cathepsin G and azurocidin. Sensitive organisms include Gram-negative bacteria such as Escherichia coli and Pseudomonas aerioginosa, and the fungus Candida albicans. Methods for preparing the compositions also are provided.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: January 22, 2002
    Assignee: Theragem, Inc.
    Inventors: Brian F. Hoffman, Ofer Binah
  • Patent number: 6337314
    Abstract: The present invention provides compositions useful as antimicrobial agents which include mammalian hemoglobin, the &agr; and &bgr; chains of hemoglobin free of heme, fragments of the &agr; and &bgr; chains that result from cyanogen bromide cleavage of the &agr; and &bgr; chains, and synthetic peptides derived therefrom. The compositions exert antimicrobial activity against both bacteria and fungi that is comparable to known antimicrobial peptides from human neutrophils, cathepsin G and azurocidin. Sensitive organisms include Gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa, Gram-positive bacteria such as Staphylococcus aureus and Streptococcus faecalis, and the fungus Candida albicans. Methods for preparing the compositions also are provided.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: January 8, 2002
    Assignee: Theragem, Inc.
    Inventors: Brian F. Hoffman, Bernard Dubnick
  • Patent number: 6329500
    Abstract: The present invention relates to a composition and method for inhibiting TGF-&bgr; activity. The composition comprises a TGF-&bgr; neutralizing peptide derived from &agr;2-macroglobulin that binds to TGF-&bgr; and inhibits TGF-&bgr; activity.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: December 11, 2001
    Assignee: University of Virginia Patent Foundation
    Inventors: Donna J. Webb, Steven L. Gonias
  • Patent number: 6307015
    Abstract: The present invention relates to the isolation of gene sequences encoding mammalian cell cycle checkpoints, as well as the expression of the encoded proteins using recombinant DNA technology. The expressed proteins are used to generate specific antibodies and to inhibit the growth of cells. The human checkpoint gene sequences are used as a probe for a portion of the chromosome associated with tumors and other malignancies, as well as growth and/or development deficiencies.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: October 23, 2001
    Assignee: Baylor College of Medicine
    Inventors: Stephen J. Elledge, Yolanda Sanchez
  • Patent number: 6303123
    Abstract: Immunogenic compositions capable of generating an immune response in mammals against GnRH are disclosed. The immunogenic compositions are effective in methods of treating gonadotropin and gonadal steroid hormone dependent diseases and immunological contraception of mammals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 16, 2001
    Assignee: Aphton Corporation
    Inventors: Stephen Grimes, Robert Scibienski
  • Patent number: 6297368
    Abstract: The present invention provides a novel MHRII-associated protein designated MHRII-AP62 and antibodies immunoreactive with the MHRII-AP62 protein. Also provided are kits containing these antibodies and methods of using the antibodies for the detection of the MHRII-AP62 protein. The present invention also provides for a nucleic acid encoding the MHRII-AP62 protein and nucleic acid probes for use in the detection of the MHRII-AP62 protein. Further provided by the present invention are agents that mimic the activity of the MHRII-AP62 protein by binding to the MHRII, agents that inhibit the activity of the MHRII-AP62 protein by binding to the MHRII-AP62 protein, or by binding to the nucleic acid encoding the MHRII-AP62 protein, and methods of using these agents to treat cancer and cancer causing diseases.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: October 2, 2001
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Ronald A. DePinho
  • Patent number: 6258779
    Abstract: The present invention provides the methods to isolate the proteins specifically induced apoptosis (programmed cell death) in prostate cancer cells (LNCAP), leukemia cells (HL-60), and breast cancer cells (MCF-70), but without effect in normal human lung fibroblast cells (CCD 39 Lu). P-1 has no effect on breast cancer cells. Five proteins have been isolated from the conditioned media of culture cells: (1) Apogen P-1: the proteins (Apogen P-1a, Apogen P-1b and Apogen P-1c) isolated from the conditioned medium of XC cells are able to induce apoptosis in prostate cancer cells (LNCAP) without effect in normal human lung fibroblast (CCD 39 Lu), colon cancer (T84), breast cancer (MCF-7) and leukemia (HL-60) cells. (2) Apogen P-2: the protein isolated from the conditioned medium of C3H1OT1/2 cells is able to induce apoptosis in prostate cancer cells (LNCAP) and breast cancer (MCF-7) without effect in normal human lung fibroblast (CCD 39 Lu) and colon cancer (T84) cells.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: July 10, 2001
    Inventors: David Tsai, Jenny Yu
  • Patent number: 6255073
    Abstract: Materials and methods of activating T lymphocytes with specificity for particular antigenic peptides are described, as well as the use of activated T lymphocytes in vitro for the treatment of a variety of disease conditions. In particular, fragments of cells for activating T lymphocytes to a specific peptide are described.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: July 3, 2001
    Assignee: The Scripps Research Institute
    Inventors: Zeling Cai, Jonathan Sprent, Anders Brunmark, Michael Jackson, Per A. Peterson
  • Patent number: 6242579
    Abstract: The subject invention pertains to an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells and binds to monoclonal antibody MG1. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: June 5, 2001
    Inventors: Michael J. P. Lawman, Patricia Lawman
  • Patent number: 6214789
    Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
    Type: Grant
    Filed: April 1, 1996
    Date of Patent: April 10, 2001
    Assignee: Xoma Corporation
    Inventor: Lewis H. Lambert, Jr.
  • Patent number: 6214343
    Abstract: Methods are described for preventing and treating necrotizing enterocolitis in animals, including humans. Antibodies directed to PAF and/or TNF are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of necrotizing enterocolitis, which is a major life-threatening illness in neonates worldwide.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: April 10, 2001
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: John A. Kink, Katherine L. Worledge
  • Patent number: 6168926
    Abstract: An nNOS associated protein designated PIN-1 (Protein Inhibitor of nNOS) has been identified. It physically interacts with nNOS and inhibits its activity. Multiple lines of evidence indicate that PIN-1 is a regulator of nNOS: it is physiologically associated with nNOS, and it inhibits its catalytic activity. The extraordinary evolutionary conservation of PIN-1 and preliminary evidence that it interacts with multiple proteins, suggests that it may be a major biological regulatory protein influencing numerous physiological processes.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: January 2, 2001
    Assignee: The Johns Hopkins University
    Inventors: Solomon H. Snyder, Samie R. Jaffrey
  • Patent number: 6166178
    Abstract: The invention provides compositions and methods related to telomerase reverse transcriptase, the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: December 26, 2000
    Assignees: University Technology Corporation, Geron Corporation
    Inventors: Thomas R. Cech, Joachim Lingner
  • Patent number: 6136959
    Abstract: A process for isolating edible protein from animal muscle by solubilizing the protein in an alkaline aqueous solution is disclosed.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: October 24, 2000
    Assignee: University of Massachusetts
    Inventors: Herbert O. Hultin, Stephen D. Kelleher
  • Patent number: 6132729
    Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: October 17, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Steven W. King, Boning Gao
  • Patent number: 6132720
    Abstract: Immunogenic compositions capable of generating an immune response in mammals against GnRH are disclosed. The immunogenic compositions are effective in methods of treating gonadotropin and gonadal steroid hormone dependent diseases and immunological contraception of mammals.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: October 17, 2000
    Assignee: Aphton Corp.
    Inventors: Stephen Grimes, Robert Scibienski
  • Patent number: 6132730
    Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: October 17, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Steven W. King, Boning Gao